FutureTech II Acquisition announces amended merger agreement with Longevity Biomedical

FutureTech II Acquisition Corp. (NASDAQ:FTII), currently trading at $12.30 with a market capitalization of $52.8 million, reported Monday it entered into an amended and restated merger agreement with Longevity Biomedical, Inc., according to a press release statement based on a recent SEC filing. InvestingPro analysis indicates the company’s overall financial health score is currently rated as WEAK.

As outlined in the agreement dated August 12, 2025, FutureTech II, Longevity Biomedical, LBI Merger Sub, Inc., and a seller representative agreed to a transaction structure involving multiple steps. First, Longevity Biomedical will complete the acquisitions of Cerevast Medical (TASE:BLWV), Inc. and Aegeria Soft Tissue, LLC, as specified in separate agreements. With the company’s next earnings report due on August 21, 2025, InvestingPro data shows the stock’s RSI currently indicates overbought territory.

Immediately following these acquisitions, FutureTech II will merge with and into a newly formed public company, referred to as PubCo, which will become the surviving entity. Subsequently, Longevity Biomedical will merge with LBI Merger Sub, Inc., with Longevity remaining as a wholly owned subsidiary of PubCo.

Upon closing, PubCo’s common stock is expected to be listed on the Nasdaq Stock Market under the ticker symbol "LBIO." The closing date will be determined upon satisfaction of the conditions outlined in the merger agreement.

Additionally, on August 12, 2025, FutureTech II approved a waiver allowing Longevity Biomedical to enter into an agreement with Aegeria Soft Tissue, LLC. This waiver removes a restriction that previously prevented Aegeria from soliciting or negotiating alternative acquisition proposals.

Copies of the approval of waiver and the waiver agreement were filed as exhibits to the SEC report.

This announcement is based solely on information disclosed in a press release statement and the related SEC filing. Investors seeking deeper insights can access additional financial metrics and analysis through InvestingPro, which offers comprehensive coverage including 6 key ProTips and over 30 financial indicators for FTII.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.